和胃胶囊治疗胃食管返流病的临床研究

目的 :评价和胃胶囊治疗胃食管返流病的临床疗效。方法 :对 30例GERD患者随机分为和胃胶囊治疗组和莫沙比利对照组 ,治疗 8周 ,观察治疗前后食道动力及 2 4h食管PH监测情况。结果 :治疗组治疗前后LESP为 (2 5 2± 0 5 5 )、(9 2 8± 3 4 5 ) ,LESRR为 (0 6 8± 0 12 )、(0 94± 0 0 5 ) ,收缩不协调比例为 (0 5 8± 0 12 )、(0 16± 0 0 8)治疗前后相比均P <0 0 5。治疗组治疗前后食管PH <4时间、PH <4所占百分比、长时间酸返流次数、最长酸返流时间、酸返流总次数分别为 (18 12± 16 88)、(5 38± 5 12 ) ;(7 2 2± 3 0 2 )、(2 0 6± 2 2 7) ;(8 90± 5 2 3)、(2 81± 1 12 ) ;(2 0 4 2± 32 90 )、(4 2 1± 3 74 ) ;(88 5 0± 36 6 5 )、(32 2 5± 15 13)治疗前后相比均P <0 0 5。与对照组相比 ,治疗组在改善食道收缩不协调比例、改善长时间酸返流次数方面 ,P <0 0 1。结论 :和胃胶囊能改善GERD患者的LESP、LESRR、收缩不协调比例 。

Effects of Shenmai Injection on Blood SOD Activity and MDA Level in Senile Patients with Coronary Heart Disease

In order to approach the effects of Shenmai Injection on SOD activity and MDA level in the senile patients with coronary heart disease, 48 cases, who had stenosis of over 70% in more than one branches of the coronary arteries, were assigned randomly into a treatment group (given Shenmai Injection plus the routine treatment) and a control group (given the routine treatment only). The superoxide dismutase (SOD) activity and malondialdehyde (MDA) level were determined before treatment and at the end of a 3-week treatment. The results showed that in the treatment group, the SOD activity was significantly increased (P＜0.05) and the MDA level markedly decreased (P＜0.01) in the treatment group. It can be concluded that Shenmai Injection may enhance the antioxidant ability of the senile patients with coronary heart disease.